Boardroom Alpha
Start trial
10-K primary document
ONC · Annual Report (Form 10-K) · Filed February 26, 2026

Beone Medicines Ltd — 10-K exhibit

exhibit1046-amgendll3waiver.htm
Beone Medicines Ltd on Boardroom Alpha
Document
image_2.jpg
Exhibit 10.4.6

CERTAIN INFORMATION (INDICATED BY “[…***…]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

October 1, 2025

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799
United States
Attention: Corporate Secretary

Re: Waiver of Certain Rights Related to […***…]-Targeting Molecules Under the Collaboration Agreement
Dear Sir or Madam:
Reference is made to that certain Collaboration Agreement, dated as of October 31, 2019 (as amended on April 20, 2022 and February 26, 2023, the “Collaboration Agreement”), by and among Amgen Inc. (“Amgen”), BeOne Medicines I GmbH (f/k/a BeiGene Switzerland GmbH) (“BeOne”) and, solely with respect to Section 13.6, BeOne Medicines Ltd. (f/k/a BeiGene, Ltd.). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Collaboration Agreement.
Amgen has notified BeOne that Amgen is undergoing discussions with a potential counterparty (“Counterparty”) regarding a […***…] combination study with Amgen’s IMDELLTRA® and Counterparty’s […***…] (the “Counterparty […***…] Product” and the “Study”).
In accordance with Section 15.16 (Waivers and Modifications) of the Collaboration Agreement, this letter serves to document BeOne’s and Amgen’s agreement that, with respect to the Counterparty […***…] Product, the Distracting Program Restrictions under Article IX of the Collaboration Agreement are hereby waived by the Parties in relation to the Study.
Please acknowledge your agreement and consent to the foregoing by counter-signing this letter agreement in the space provided below and returning a copy to us.

[Signature Page Follows]

image_2.jpg
Yours sincerely,
BEONE MEDICINES I GMBH
/s/ Michael Schoen
By: Michael Schoen
Title: Managing Director
BEONE MEDICINES LTD.
/s/ Chan Lee
By: Chan Lee
Title: SVP, General Counsel and Corporate Secretary


Acknowledged and agreed:
AMGEN INC.
/s/ Rachna Khosla
By: Rachna Khosla
Title: SVP, Business Development


BeOne Medicines I GmbH
Aeschengraben 27
4051 Basel, Switzerland
BeOneMedicines.com
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer